Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641089 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
A Phase 3 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06641089 is a Phase 3 study of Arthritis, Psoriatic that is actively recruiting participants, run by MoonLake Immunotherapeutics. The registered enrollment target is 600 participants, above the 539-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06641089, a Phase 3 study of Arthritis, Psoriatic, is actively recruiting participants, sponsored by MoonLake Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sonelokimab
- DRUG Risankizumab
Study Locations (20)
Arizona
- Clinical Site - Avondale
- Clinical Site - Chandler
- Clinical Site - Flagstaff
- Clinical Site - Mesa
- Clinical Site - Phoenix
- Clinical Site - Scottsdale
- Clinical Site - Tucson
California
- Clinical Site - La Jolla
- Clinical Site - Pomona
- Clinical Site - San Diego
- Clinical Site - Santa Monica
- Clinical Site - Thousand Oaks
- Clinical Site - Upland
Florida
- Clinical Site - Avon Park
- Clinical Site - Clearwater
- Clinical Site - Hialeah
- Clinical Site - Miami Gardens
- Clinical Site - Tampa
- Clinical Site - Zephyrhills
Arkansas
- Clinical Site - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06641089
The ClinicalTrials.gov registry entry for NCT06641089 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 539-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (11% higher). The listed sponsor is MoonLake Immunotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06641089 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06641089 about?
NCT06641089 is a clinical study titled "Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response". This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
What is the current status of trial NCT06641089?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2024-10-15. Estimated completion is 2027-01-15.
What conditions does trial NCT06641089 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT06641089?
The interventions under investigation include: Placebo (DRUG), Sonelokimab (DRUG), Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06641089?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641089 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.